Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) vs Lyra Therapeutics, Inc. (LYRA)

Biodexa Pharmaceuticals PLC Unsponsored ADR and Lyra Therapeutics, Inc. are both Biotechnology companies. Lyra Therapeutics, Inc. is the larger, with a market value of $870.0K against $700.0K — 1.2× the size. Biodexa Pharmaceuticals PLC Unsponsored ADR grew revenue faster over the last twelve months: 60.2% against −74.1%. Biodexa Pharmaceuticals PLC Unsponsored ADR has the higher net margin (−1,155.7% vs −7,266.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Biodexa Pharmaceuticals PLC Unsponsored ADR leads on 11 and Lyra Therapeutics, Inc. on 4.

Valuation

Metric BDRX LYRA Biotechnology median
P/E n/m n/m 7.88
P/S n/m 0.78 11.47
P/B n/m n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.20 0.51 0.74
EV/Sales (2.81) (39.15) 10.73
Earnings yield (375.47%) (9,575.00%) (28.84%)
Free cash flow yield 0.00% (9,304.25%) (23.03%)

Profitability

Metric BDRX LYRA Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (7,794.47%) 0.00%
Net margin (1,155.70%) (7,266.08%) 0.00%
Free cash flow margin 0.00% (7,261.06%) 0.00%
Return on equity 0.00% (6,594.98%) (57.72%)
Return on assets 0.00% (56.45%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BDRX LYRA Biotechnology median
Revenue growth (TTM) 60.22% (74.05%) 5.64%
EPS growth (last fiscal year) 89.68% 73.96% —
Revenue growth, 5-year CAGR (28.78%) (20.38%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BDRX LYRA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.41 1.71 4.73
Net debt to EBITDA 1.00 0.52 0.96

Dividend

Metric BDRX LYRA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BDRX LYRA Biotechnology median
Market cap 700.00k 870.00k 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack